Peptides DB

Research-centric peptide and protocol reference hub

ARA 290 vs Thymosin Alpha-1

Updated July 23, 2026 · Reviewed by the PeptidesDB Editorial team

ARA 290: Research use — not FDA-approvedThymosin Alpha-1: Research use — not FDA-approved

A data-driven comparison of ARA 290 and Thymosin Alpha-1 (also searched as Thymosin Alpha-1 vs ARA 290) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

ARA 290 centers on neuro, while Thymosin Alpha-1 leans toward healing. On indexed research, Thymosin Alpha-1 is ahead (ARA 290: 4 studies, Preclinical; Thymosin Alpha-1: 5, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • ARA 290 is strongest for neuro; Thymosin Alpha-1 for healing.
  • Evidence: ARA 290 Preclinical (4 studies) vs Thymosin Alpha-1 Human clinical (5).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
ARA 290Thymosin Alpha-1

At a glance

ARA 290Preclinical

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Strongest: NeuroStudies: 4Level: Extensively Studied
Thymosin Alpha-1Human clinical

Synthetic Thymic Hormone | Immune System Modulator

Strongest: HealingStudies: 5Level: Well Studied

ARA 290 vs Thymosin Alpha-1: side-by-side

MetricARA 290Thymosin Alpha-1
ClassHealingImmune
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalHuman clinical
Studies indexed45
Research levelExtensively StudiedWell Studied
Strongest effectNeuro & moodHealing & recovery
Healing & recovery2.34.0
Muscle & body comp2.20.0
Metabolic & appetite1.70.0
Neuro & mood3.00.0
Sleep & circadian1.00.0
Inflammation & immune2.74.0
Skin & aesthetics2.20.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyARA 290Thymosin Alpha-1
MechanismEnhances T-cell function and promotes maturation of immune cells

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is Thymosin Alpha-1?

### Thymosin Alpha-1 Summary Thymosin Alpha-1 (Tα1) is a peptide that plays a crucial role in modulating immune responses and has been investigated for its potential therapeutic applications in various conditions, including infections and inflammatory diseases.

Full Thymosin Alpha-1 profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingThymosin Alpha-14.0/5 effect signal
MuscleARA 2902.2/5 effect signal
MetabolicARA 2901.7/5 effect signal
NeuroARA 2903.0/5 effect signal
SleepARA 2901.0/5 effect signal
InflammationThymosin Alpha-14.0/5 effect signal
SkinARA 2902.2/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack ARA 290 and Thymosin Alpha-1?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

ARA 290 vs Thymosin Alpha-1: side effects

ARA 290

No community-reported effects logged yet.

Thymosin Alpha-1

No community-reported effects logged yet.

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

ARA 290 has 4 approved studies indexed (Preclinical), and Thymosin Alpha-1 has 5 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is ARA 290 or Thymosin Alpha-1 better?

It depends on your goal. ARA 290 is strongest for neuro; Thymosin Alpha-1 for healing. Thymosin Alpha-1 has more indexed studies (5). See the goal-by-goal breakdown above.

Is ARA 290 or Thymosin Alpha-1 better for weight loss?

ARA 290 shows the stronger metabolic & appetite profile (1.7/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is ARA 290 or Thymosin Alpha-1 better for muscle?

ARA 290 leads on the muscle & body-composition axis (2.2/5).

Which has more research, ARA 290 or Thymosin Alpha-1?

ARA 290 has 4 approved studies indexed (Preclinical); Thymosin Alpha-1 has 5 (Human clinical). Higher counts mean more to read, not proven superiority.

Can you stack ARA 290 and Thymosin Alpha-1?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of ARA 290 vs Thymosin Alpha-1?

ARA 290: no community-reported effects logged yet. Thymosin Alpha-1: none logged yet. These are anonymous reports, not incidence rates — see each profile.

Is ARA 290 or Thymosin Alpha-1 FDA-approved?

ARA 290 is a research-use compound and is not FDA-approved. Thymosin Alpha-1 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is Thymosin Alpha-1 better than ARA 290?

For healing, Thymosin Alpha-1 has the edge; for neuro, ARA 290 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

ARA 290 and Thymosin Alpha-1 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 23, 2026.